Publications by authors named "S Gkalpakiotis"
Introduction: Alopecia areata is a common autoimmune disease which results in reversible hair loss. Janus kinase inhibitors are prescribed for severe alopecia areata with encouraging results. There are no studies comparing the efficacy and safety of Janus kinase inhibitors to traditional treatment options, such as topical immunomodulators and traditional immunosuppressants.
View Article and Find Full Text PDFIntroduction: The aim of this observational, multicenter study was to assess the real-world use of brodalumab for the treatment of moderate-to-severe plaque psoriasis in patients in the Czech Republic, using data from the BIOREP registry.
Methods: The study included 273 patients aged ≥ 18 years with moderate-to-severe psoriasis who received brodalumab. Endpoints were drug survival (time from treatment initiation to discontinuation), effectiveness [Psoriasis Area and Severity Index (PASI)], and health-related quality-of-life [Dermatology Life Quality Index (DLQI)].
Article Synopsis
- The study aimed to analyze how well biologic drugs (IL-23 and IL-17 inhibitors) work for treating psoriasis in patients aged 65 and older compared to younger patients.
- It found that elderly patients had a higher risk of discontinuing treatment, especially with IL-23 inhibitors, while IL-17 inhibitors didn't show a significant difference.
- Additionally, factors like previous treatments influenced the likelihood of continuing or stopping the medication in elderly patients.
Introduction: Limited real-world evidence exists about the burden of atopic dermatitis (AD) in patients receiving systemic or non-systemic therapies in clinical practices. ESSENTIAL AD was an observational study that aimed to fill this information gap.
Methods: ESSENTIAL AD enrolled (September 2021-June 2022) adult patients with physician-confirmed AD that was routinely managed with systemic and non-systemic treatment in a real-world setting from 15 countries in Eastern Europe, the Middle East, and Africa.
Article Synopsis
- Tralokinumab is a monoclonal antibody approved for moderate to severe atopic dermatitis, but real-world studies on its effectiveness and safety are limited.
- A European retrospective cohort study with 194 adult patients evaluated tralokinumab's performance over 32 weeks, measuring improvement in disease severity and quality of life.
- Results showed significant improvements in symptoms, with 88% of patients meeting treatment goals, and similar outcomes across different age groups and treatment histories.